Fanconi syndrome: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 16: | Line 16: | ||
{{Fanconi syndrome}} | {{Fanconi syndrome}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{VE}} | ||
{{SK}} Proximal renal tubular acidosis; RTA2; Fanconi's syndrome; De Toni-Fanconi syndrome | {{SK}} Proximal renal tubular acidosis; RTA2; Fanconi's syndrome; De Toni-Fanconi syndrome | ||
Line 31: | Line 31: | ||
==[[Fanconi syndrome epidemiology and demographics|Epidemiology and Demographics]]== | ==[[Fanconi syndrome epidemiology and demographics|Epidemiology and Demographics]]== | ||
==[[Fanconi syndrome natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | ==[[Fanconi syndrome natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | ||
Line 48: | Line 46: | ||
{{Metabolic pathology}} | {{Metabolic pathology}} | ||
{{Nephrology}} | {{Nephrology}} | ||
[[Category:Organ disorders]] | [[Category:Organ disorders]] |
Latest revision as of 16:16, 21 July 2018
Fanconi syndrome | |
ICD-10 | E72.0 |
---|---|
ICD-9 | 270.0 |
DiseasesDB | 11687 |
MeSH | D005198 |
For patient information, click here.
Fanconi syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Fanconi syndrome On the Web |
American Roentgen Ray Society Images of Fanconi syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vahid Eidkhani, M.D.
Synonyms and keywords: Proximal renal tubular acidosis; RTA2; Fanconi's syndrome; De Toni-Fanconi syndrome
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Fanconi syndrome from other Diseases
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | X Ray | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies